Literature DB >> 26251001

Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus.

Petter Bjornstad1, Robert H Eckel2, Laura Pyle3, Marian Rewers4, David M Maahs4, Janet K Snell-Bergeon4.   

Abstract

Apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) are cardiovascular disease risk markers, although data in adults with type 1 diabetes mellitus (DM) are limited. We hypothesized that elevated apoB and non-HDL-C would be associated with greater odds of coronary artery calcification progression (CACp), a measure of coronary atherosclerosis, than either category alone in adults with type 1 DM. We grouped subjects with type 1 DM (n = 652) into 4 groups: elevated apoB (≥90 mg/dl) and elevated non-HDL-C (≥130 mg/dl), elevated non-HDL-C alone, elevated apoB alone, and normal apoB and non-HDL-C. We used logistic regression to examine the associations between the groups and CACp for a period of 6 years. We performed sensitivity analyses with elevated apoB and non-HDL-C redefined as at or more than the cohort means (91.4 and 119.0 mg/dl, respectively). Subjects with elevated apoB and non-HDL-C had greater odds of CACp compared with those with normal apoB and non-HDL-C (odds ratio 1.90, 95% confidence interval 1.15 to 3.15) and compared with subjects with elevated apoB alone (odds ratio 2.86, 95% confidence interval 1.43 to 5.74) adjusting for age, gender, duration, hemoglobin A1c, and statins. Similar results were obtained with elevated apoB and non-HDL-C defined as at or more than the cohort means. In conclusion, elevated apoB and non-HDL-C carry a greater risk of atherosclerosis than elevated apoB in the absence of elevated non-HDL-C in adults with type 1 DM. These data suggest that apoB and non-HDL-C should be viewed as complementary rather than competitive indexes of cardiovascular disease risk in type 1 DM.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26251001      PMCID: PMC4567927          DOI: 10.1016/j.amjcard.2015.07.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality.

Authors:  Leslee J Shaw; Paolo Raggi; Enrique Schisterman; Daniel S Berman; Tracy Q Callister
Journal:  Radiology       Date:  2003-07-17       Impact factor: 11.105

3.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 4.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

5.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

6.  Tracking of serum apolipoproteins A-I and B in children and young adults: the Bogalusa Heart Study.

Authors:  W Bao; S R Srinivasan; G S Berenson
Journal:  J Clin Epidemiol       Date:  1993-07       Impact factor: 6.437

7.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

8.  Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Authors:  Allan D Sniderman; Annie C St-Pierre; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

9.  Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.

Authors:  Markus Juonala; Jorma S A Viikari; Mika Kähönen; Tiina Solakivi; Hans Helenius; Antti Jula; Jukka Marniemi; Leena Taittonen; Tomi Laitinen; Tapio Nikkari; Olli T Raitakari
Journal:  J Am Coll Cardiol       Date:  2008-07-22       Impact factor: 24.094

10.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Authors:  P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

View more
  6 in total

Review 1.  Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.

Authors:  Petter Bjornstad; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2018-10-17       Impact factor: 4.810

2.  Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study.

Authors:  S Sayols-Baixeras; I Subirana; C Lluis-Ganella; F Civeira; J Roquer; A N Do; D Absher; A Cenarro; D Muñoz; C Soriano-Tárraga; J Jiménez-Conde; J M Ordovas; M Senti; S Aslibekyan; J Marrugat; D K Arnett; R Elosua
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

3.  Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.

Authors:  Teresa Buckner; Baohai Shao; Robert H Eckel; Jay W Heinecke; Karin E Bornfeldt; Janet Snell-Bergeon
Journal:  J Clin Lipidol       Date:  2020-10-31       Impact factor: 5.365

4.  Beneficial Effects of Pterocarpan-High Soybean Leaf Extract on Metabolic Syndrome in Overweight and Obese Korean Subjects: Randomized Controlled Trial.

Authors:  Ri Ryu; Tae-Sook Jeong; Ye Jin Kim; Ji-Young Choi; Su-Jung Cho; Eun-Young Kwon; Un Ju Jung; Hyeon-Seon Ji; Dong-Ha Shin; Myung-Sook Choi
Journal:  Nutrients       Date:  2016-11-18       Impact factor: 5.717

5.  Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.

Authors:  Evgenia Gourgari; Martin P Playford; Umberto Campia; Amit K Dey; Fran Cogen; Stephanie Gubb-Weiser; Mihriye Mete; Sameer Desale; Maureen Sampson; Allen Taylor; Kristina I Rother; Alan T Remaley; Nehal N Mehta
Journal:  Cardiovasc Diabetol       Date:  2018-12-19       Impact factor: 9.951

6.  Spectrophotometry and Ultracentrifugation for Measurement of Plasma Lipids in Dogs with Diabetes Mellitus.

Authors:  E C Seage; K J Drobatz; R S Hess
Journal:  J Vet Intern Med       Date:  2017-11-29       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.